CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath

Blood. 2002 Nov 15;100(10):3843-4. doi: 10.1182/blood-2002-08-2398.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adult
  • Alemtuzumab
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / adverse effects*
  • Antineoplastic Agents / adverse effects*
  • Cytomegalovirus Infections / chemically induced*
  • Female
  • Hematologic Neoplasms / complications
  • Hematologic Neoplasms / therapy
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Male
  • Middle Aged
  • Transplantation Conditioning / adverse effects
  • Transplantation Conditioning / methods
  • Transplantation, Homologous / adverse effects

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Immunosuppressive Agents
  • Alemtuzumab